Michel Detheux headed during 8 years Euroscreen multidisciplinary team of 22 people dedicated to new target validation. He moved to bus dev and was involved in negotiation of deals with Cephalon, Novartis and Medarex. In 2006, he was promoted as Executive Director to create and manage Euroscreen FAST, a CRO for in vitro testing of drug candidates in preclinical development. He joined Ludwig Institute to create iTeos at the end of 2010

• B. Van den Eynde is the Director of the LICR Brussels Branch. He has an internationally recognized expertise in tumor immunology, with identification of some of the very first tumor antigens, antisense transcription and translation of alternative open-reading frames and the peptide splicing by the proteasome. His group was also the first one to demonstrate specific immunosuppressive mechanisms. He has received several awards during his career.